
Year
DEALS // DEV.
Country
Therapeutic Area
Study Phase
Deal Type
Product Type
Dosage Form
Lead Product
Target

Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass.
Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.
Lead Product(s) : OP-175
Therapeutic Area : Nutrition and Weight Loss
Study Phase : Preclinical
Sponsor : Omega Funds
Deal Size : Undisclosed
Deal Type : Financing
Ousia Pharma Secures Seed Funding Led by Omega Funds for Obesity Treatment
Details : The financing will support the development of a dual-incretin-NMDA receptor antagonist conjugate through preclinical and early clinical development for the treatment of obesity.
Product Name : Undisclosed
Product Type : Peptide-drug Conjugate
Upfront Cash : Undisclosed
May 06, 2025
Lead Product(s) : OP-175
Therapeutic Area : Nutrition and Weight Loss
Highest Development Status : Preclinical
Sponsor : Omega Funds
Deal Size : Undisclosed
Deal Type : Financing
